Compass Therapeutics, Inc.
About Compass Therapeutics, Inc.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$66.5M
- Total assets
- $219.6M
- Market cap
- $367.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $72.8M
- Operating income
- -$72.8M
- Income tax
- $0
- Net income
- -$66.5M
- EPS (basic)
- $-0.42
Balance sheet
- Total assets
- $219.6M
- Current assets
- $209.8M
- Total liabilities
- $22.8M
- Current liabilities
- $14.0M
- Shareholders’ equity
- $196.8M
Cash flow
- Operating cash flow
- -$49.1M
- Investing cash flow
- -$93.3M
- Financing cash flow
- $129.6M
- Net cash flow
- -$12.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $367.4M
- Shares outstanding
- 181.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 13, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $66.5M.
- Trading 70% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Compass Therapeutics, Inc..
Write a review
News about Compass Therapeutics, Inc.
News & sentiment via Polygon.io
